FDA green-lights addiction drug amid opioid controversy

The FDA has said repeatedly that it's committed to fighting the opioid epidemic, and to that end, it approved BioDelivery Sciences' ($BDSI) Bunavail Friday to treat dependence on the drugs. BioDelivery said it expects to launch the new med late in this year's third quarter, and its market currently tallies more than two million people in the U.S. The FDA has recently had to answer for its move to keep potent opioid painkiller Zohydro on the market despite worries that it lends itself to abuse. Since the controversy bubbled up, the agency has also approved Evzio, an EpiPen-like handheld device containing a drug that can reverse the effects of an overdose. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.